Most people haven’t heard of the condition, but Friedreich’s ataxia is getting more attention because of a new treatment and a large number of clinical trials enrolling people with the condition.
Researchers to Clinicians: Don’t Neglect the Neuropsychiatric Symptoms of Friedreich’s Ataxia
November 27th 2024Poor balance and coordination are prominent features of Friedreich’s ataxia (FRDA). Czech researchers found that neuropsychiatric symptoms are also common among patients with FRDA.
Read More
Ethical Considerations of Friedreich’s Ataxia Treatment
November 15th 2024As novel gene therapies emerge, there is a complex interplay among their potential benefits, the burdens they may impose and the risks involved, particularly when treating vulnerable populations such as children.
Read More
Wearable Devices Help Assess Friedreich's Ataxia Severity Better Than In-Clinic Assessments
November 4th 2024The ability to gather continuous, objective data on physical activity and upper limb movements may allow for a more comprehensive understanding of the daily functional capacities of patients with Friedereich's ataxia.
Read More
Positive Pipeline Updates for Friedreich’s Ataxia
October 24th 2024After experiencing setbacks, PTC reported positive results for vatiquinone, its selective inhibitor of 15-Lipoxygenase (15-LO) enzyme, regulator of the energetic and oxidative stress pathways that are disrupted in Friedreich ataxia
Read More
Early Genetic Testing Avoids Treatment Delays for Patients with Friedreich's Ataxia
September 18th 2024Genetic and biochemical testing are crucial for improving outcomes for patients with Friedreich ataxia, according to speakers at a symposium at the European Association of Neurology Congress.
Read More